JP2022500410A5 - - Google Patents

Info

Publication number
JP2022500410A5
JP2022500410A5 JP2021513868A JP2021513868A JP2022500410A5 JP 2022500410 A5 JP2022500410 A5 JP 2022500410A5 JP 2021513868 A JP2021513868 A JP 2021513868A JP 2021513868 A JP2021513868 A JP 2021513868A JP 2022500410 A5 JP2022500410 A5 JP 2022500410A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
antagonist
heavy chain
light chain
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021513868A
Other languages
English (en)
Japanese (ja)
Other versions
JP7470105B2 (ja
JP2022500410A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/050122 external-priority patent/WO2020055702A1/en
Publication of JP2022500410A publication Critical patent/JP2022500410A/ja
Publication of JP2022500410A5 publication Critical patent/JP2022500410A5/ja
Application granted granted Critical
Publication of JP7470105B2 publication Critical patent/JP7470105B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021513868A 2018-09-13 2019-09-09 非マイクロサテライト高不安定性/ミスマッチ修復の良好な結腸直腸がんを処置するためのpd-1アンタゴニストおよびlag3アンタゴニストの組み合わせ Active JP7470105B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862730772P 2018-09-13 2018-09-13
US62/730,772 2018-09-13
US201862755844P 2018-11-05 2018-11-05
US62/755,844 2018-11-05
PCT/US2019/050122 WO2020055702A1 (en) 2018-09-13 2019-09-09 Combination of pd-1 antagonist and lag3 antagonist for treating non-microsatellite instablity-high/proficient mismatch repair colorectal cancer

Publications (3)

Publication Number Publication Date
JP2022500410A JP2022500410A (ja) 2022-01-04
JP2022500410A5 true JP2022500410A5 (cg-RX-API-DMAC7.html) 2022-09-01
JP7470105B2 JP7470105B2 (ja) 2024-04-17

Family

ID=69776882

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021513868A Active JP7470105B2 (ja) 2018-09-13 2019-09-09 非マイクロサテライト高不安定性/ミスマッチ修復の良好な結腸直腸がんを処置するためのpd-1アンタゴニストおよびlag3アンタゴニストの組み合わせ

Country Status (6)

Country Link
US (1) US20210317214A1 (cg-RX-API-DMAC7.html)
EP (1) EP3849606A4 (cg-RX-API-DMAC7.html)
JP (1) JP7470105B2 (cg-RX-API-DMAC7.html)
AU (1) AU2019337547A1 (cg-RX-API-DMAC7.html)
CA (1) CA3111066A1 (cg-RX-API-DMAC7.html)
WO (1) WO2020055702A1 (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2831084T3 (es) 2016-06-10 2021-06-07 Vitae Pharmaceuticals Inc Inhibidores de la interacción menina-MLL
WO2020096917A1 (en) * 2018-11-05 2020-05-14 Merck Sharp & Dohme Corp. Dosing regimen of anti-lag3 antibody and combination therapy with anti-pd-1 antibody for treating cancer
IL297039A (en) 2020-04-07 2022-12-01 Syndax Pharmaceuticals Inc Combinations of menin inhibitors and cyp3a4 inhibitors and methods of use thereof
CA3196496A1 (en) 2020-10-23 2022-04-28 Laurence David TOMS Lag-3 antagonist therapy for lung cancer
AR125866A1 (es) 2021-05-14 2023-08-23 Syndax Pharmaceuticals Inc Inhibidores de la interacción de menina-mll
KR20240153583A (ko) * 2022-02-25 2024-10-23 브리스톨-마이어스 스큅 컴퍼니 결장직장암종에 대한 병용 요법
CN120514709A (zh) * 2022-05-09 2025-08-22 赛达克斯制药股份有限公司 用于治疗癌症的menin-mll抑制剂
WO2026035866A1 (en) 2024-08-07 2026-02-12 Iovance Biotherapeutics, Inc. Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with a lag-3 inhibitor and a pd-1 inhibitor
KR20260116273A (ko) 2024-09-20 2026-07-28 파라곤 테라퓨틱스, 인크. Pd-1 결합 단백질, vegf 및 pd-1 이중특이적 결합 단백질, 조성물 및 사용 방법

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
WO2000032634A1 (en) 1998-12-01 2000-06-08 Protein Design Labs, Inc. Humanized antibodies to gamma-interferon
DE60334303D1 (de) 2002-07-03 2010-11-04 Tasuku Honjo Immunpotenzierende zusammensetzungen
ES2367430T3 (es) 2002-12-23 2011-11-03 Wyeth Llc Anticuerpos contra pd-1 y sus usos.
US7563869B2 (en) 2003-01-23 2009-07-21 Ono Pharmaceutical Co., Ltd. Substance specific to human PD-1
EP3530736A3 (en) 2005-05-09 2019-11-06 ONO Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
KR101704734B1 (ko) 2005-07-01 2017-02-09 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체
PT2170959E (pt) 2007-06-18 2014-01-07 Merck Sharp & Dohme Anticorpos para o receptor humano de morte programada pd-1
US8168757B2 (en) 2008-03-12 2012-05-01 Merck Sharp & Dohme Corp. PD-1 binding proteins
WO2010098788A2 (en) 2008-08-25 2010-09-02 Amplimmune, Inc. Pd-i antagonists and methods for treating infectious disease
WO2010036959A2 (en) 2008-09-26 2010-04-01 Dana-Farber Cancer Institute Human anti-pd-1, pd-l1, and pd-l2 antibodies and uses therefor
MX356367B (es) 2008-12-09 2018-05-25 Genentech Inc Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t.
EP2504028A4 (en) 2009-11-24 2014-04-09 Amplimmune Inc SIMULTANEOUS INHIBITION OF PD-L1 / PD-L2
WO2012135408A1 (en) 2011-03-31 2012-10-04 Merck Sharp & Dohme Corp. Stable formulations of antibodies to human programmed death receptor pd-1 and related treatments
BR112014002353B1 (pt) 2011-08-01 2022-09-27 Genentech, Inc Usos de antagonistas de ligação do eixo pd-1 e inibidores de mek, composições farmacêuticas, e kit
AR093984A1 (es) 2012-12-21 2015-07-01 Merck Sharp & Dohme Anticuerpos que se unen a ligando 1 de muerte programada (pd-l1) humano
RS64268B1 (sr) * 2013-09-20 2023-07-31 Bristol Myers Squibb Co Kombinacija anti-lag-3 antitela i anti-pd-1 antitela za lečenje tumora
WO2016011357A1 (en) * 2014-07-18 2016-01-21 Advaxis, Inc. Combination of a pd-1 antagonist and a listeria-based vaccine for treating prostate cancer
JO3663B1 (ar) * 2014-08-19 2020-08-27 Merck Sharp & Dohme الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين
US20170097333A1 (en) * 2015-09-28 2017-04-06 Merck Sharp & Dohme Corp. Cell based assay to measure the t-cell stimulating capacity of anti-lag3 antibodies and other agents
TWI756187B (zh) * 2015-10-09 2022-03-01 美商再生元醫藥公司 抗lag3抗體及其用途
US10613092B2 (en) * 2016-04-01 2020-04-07 Agilent Technologies, Inc. Scoring methods for anti-PD therapy eligibility and compositions for performing same
KR102976378B1 (ko) * 2016-06-03 2026-06-11 브리스톨-마이어스 스큅 컴퍼니 결장직장암을 갖는 환자의 치료에서의 항-pd-1 항체의 용도
WO2019148412A1 (en) * 2018-02-01 2019-08-08 Merck Sharp & Dohme Corp. Anti-pd-1/lag3 bispecific antibodies

Similar Documents

Publication Publication Date Title
JP2017524715A5 (cg-RX-API-DMAC7.html)
JP2024037894A5 (cg-RX-API-DMAC7.html)
JP2019519499A5 (cg-RX-API-DMAC7.html)
JP2018508483A5 (cg-RX-API-DMAC7.html)
FI3799885T3 (fi) Lymfosyyttien estoreittien neutralointi
MX2021011500A (es) Anticuerpos multiespecificos egfr x cd28.
IL318482A (en) Pd-1 inhibitor for use in a method of treating skin cancer
RU2014147867A (ru) Способы лечения рака с применением антагонистов аксиального связывания pd-1 и vegf антагонистов
JP2018070648A5 (cg-RX-API-DMAC7.html)
JP2019515008A5 (cg-RX-API-DMAC7.html)
HRP20231156T1 (hr) Kombinacija anti-pd-1 antitijela i bispecifičnih anti-cd20/anti-cd3 antitijela za liječenje raka
IL253462B (en) Cancer treatment with monoclonal antibodies against latency-associated peptide
JP2017535257A5 (cg-RX-API-DMAC7.html)
JP2020508317A5 (cg-RX-API-DMAC7.html)
JP2022512750A5 (cg-RX-API-DMAC7.html)
JP2016537383A5 (cg-RX-API-DMAC7.html)
JP2018518454A5 (cg-RX-API-DMAC7.html)
RU2018105846A (ru) Комбинация антагониста pd-1 с ингибитором egfr
JP2018522887A5 (cg-RX-API-DMAC7.html)
MX2020008446A (es) Metodos para el tratamiento contra el cancer mediante anticuerpos anti-pd-1 y anticuerpos anti-ctla4.
WO2015200806A3 (en) Humanized anti-tau antibodies
RU2011116112A (ru) Биспецифические анти-egfr/анти-igf-1r антитела
PE20191759A1 (es) Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y usos de los mismos
JP2019524701A5 (cg-RX-API-DMAC7.html)
JP2022512851A5 (cg-RX-API-DMAC7.html)